Back
NM_001127510.3:c.6907G>A
p.Gly2303Arg · APC
0%
complete
Final classification
Benign
BA1BS1BP1
APC
c.6907G>A
p.Gly2303Arg
missense · exon 17

APC is a tumor suppressor gene whose protein acts as a key brake on the Wnt signaling pathway by helping mark the growth-promoting protein beta-catenin for destruction; it also participates in cell migration, adhesion, and apoptosis. Inherited mutations in APC cause familial adenomatous polyposis (FAP), an autosomal dominant condition characterized by numerous colorectal polyps and a very high risk of colorectal cancer, with related forms including attenuated FAP and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). Somatic APC mutations are found in roughly 50-80% of sporadic colorectal cancers, where they act as early tumor-initiating events, and are also observed in some breast, stomach, and prostate cancers. Loss of APC function leaves Wnt signaling abnormally active, driving uncontrolled cell growth, which makes APC a central tumor suppressor in colorectal cancer.

This variant

APC encodes a tumour suppressor that restrains Wnt signalling by promoting beta-catenin degradation, and germline loss-of-function APC alleles cause autosomal dominant familial adenomatous polyposis with a very high colorectal cancer risk; NM_001127510.3:c.6907G>A (p.Gly2303Arg) is a C-terminal-region missense allele present at population frequencies (up to ~0.26% in South Asian non-cancer cohorts) far above what a dominantly acting polyposis allele could sustain, and no phenotype, segregation or functional data link it to the loss-of-function mechanism underlying APC disease.

Transcript
NM_001127510.3
HGVS · transcript:coding
NM_001127510.3:c.6907G>A
GRCh38
chr5:112842501 G>A
GRCh37
chr5:112178198 G>A
Benign: BA1 (stand-alone benign) from a gnomAD v2.1 non-cancer Popmax filtering allele frequency of 0.216%, above the APC Expert Panel's 0.1% threshold.
Classification rationale
BA1BS1BP1 Benign
APC c.6907G>A missense · exon 17

BA1 (stand-alone benign): gnomAD v2.1 non-cancer Popmax filtering AF 0.216% (80/30,518 South Asian alleles) exceeds the APC VCEP 0.1% stand-alone threshold, which alone yields Benign. BS1 (strong): the same non-cancer frequency clears the APC VCEP 0.001% strong-benign bar, but it rests on the same observation as BA1 and adds no independent weight. BP1 (supporting): missense p.(Gly2303Arg) at codon 2303 sits outside the VCEP's codon 1021-1035 exception in a gene where >90% of pathogenic point mutations are truncating.

BA1 + BS1 + BP1 Benign
LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
Gene diagram · NM_001127510.3 · variants mapped to exon structure
APC NM_001127510.3
Fetching transcript structure from UCSC…
Applied criteria · 3 applied · 17 assessed
MetEvidence satisfies this criterion.
Not metEvaluated against available evidence; threshold not reached.
Not assessedApplies in principle, but no evidence was found to evaluate it.
N/ADoesn't apply to this variant type.
Applied · 3
Strength Supporting Moderate Strong Very strong
BA1 stand-alone Benign
Met: gnomAD v2.1 non-cancer Popmax FAF 0.216% (0.00216) exceeds the APC VCEP BA1 stand-alone threshold of 0.1% (0.001), driven by South Asian alleles.
APC VCEP specification v2.1 (InSiGHT Hereditary Colorectal Cancer/Polyposis Expert Panel) BA1 rule, listed strength Stand Alone: 'GnomAD Popmax Filtering Allele Frequency (AF) >= 0.1% (0.001).' The specification's instructionsToUse field for BA1 states: 'General recommendation: Use the non-cancer dataset from gnomAD (v2.1.1)'.The APC VCEP supplementary material (v2) independently states for BA1: 'Allele frequency >= 0.1% (preferably based on the P[opmax] ...)' and records a penetrance assumption of 0.8 in the same derivation table, confirming 0.1% Popmax is the governing stand-alone threshold rather than a generic 5% cut-off.gnomAD v2.1 non-cancer exomes (VCEP-designated source, GRCh37 position 5-112178198-G-A): total AF 0.000350957, 83/236,496 alleles, 1 homozygote; Popmax Filtering AF 0.00215798 (0.216%); South Asian 80/30,518 (AF 0.002621403, 1 homozygote); 'remaining individuals' 3/5,610 (AF 0.000535); zero alleles in all other ancestry groups of this subset.
BS1 strong Benign
Met: gnomAD v2.1 non-cancer Popmax FAF 0.216% (0.00216) far exceeds the APC VCEP BS1 strong threshold of 0.001% (0.00001), but BA1 supersedes it.
APC VCEP specification v2.1 BS1 rule, listed strength Strong: 'GnomAD Popmax Filtering Allele Frequency (AF) >= 0.001% (0.00001).' The specification's instructionsToUse field for BS1 states: 'General recommendation: Use the non-cancer dataset from gnomAD (v2.1.1)'.The APC VCEP supplementary material (v2) states for BS1: 'Allele frequency >= 0.001% (preferably based on the [Popmax] ...)', with penetrance 0.8 shown in the adjacent derivation table - i.e. the very low 0.001% bar reflects the dominant, highly penetrant nature of APC-associated disease.gnomAD v2.1 non-cancer exomes: Popmax Filtering AF 0.00215798 (0.216%), total AF 0.000350957 (83/236,496 alleles, 1 homozygote), South Asian 80/30,518 (AF 0.002621403).
BP1 supporting Benign
Met at supporting strength: missense p.(Gly2303Arg) at codon 2303 sits outside the VCEP's codon 1021-1035 exception in a gene where truncating variants predominate.
APC VCEP v2.1 BP1 rule text: 'BP1 is applicable to APC with the exception of missense variants located in the first 15-amino acid repeat of the beta-catenin binding domain (codon 1021-1035).'The variant under assessment is a missense change, NP_001120982.1:p.(Gly2303Arg), at codon 2303 - outside the codon 1021-1035 exception and outside the beta-catenin binding domain (codons 959-2129) as defined in the same VCEP specification - so BP1's stated exception does not exclude its use here.PMID:21368914: APC point mutations are >90% truncating (nonsense, del/ins, splice sites), the vast majority lie in the 5' half of the gene, mutations 3' to codon 1700 are rare (~1%), and reported hotspots are codons 1309, 1061, 213 and 1068 - establishing that truncating variants, not missense variants such as p.(Gly2303Arg), are the predominant cause of APC-associated disease.
Assessed · not applied · 11 not met · 6 not assessed
Pathogenic
PVS1 Not met: c.6907G>A causes a missense change, p.(Gly2303Arg), not a null variant, so the APC VCEP PVS1 decision tree is never triggered.
PS1 Not met: no established pathogenic or likely pathogenic APC variant produces p.(Gly2303Arg); the VCEP recognises only p.(Asn1026Ser) and p.(Ser1028Arg) as likely pathogenic missense changes.
PS2 Not assessed: with no proband, parental testing, or de novo observation recorded, the APC de novo score of at least 1 required for PS2 cannot be computed.
PS3 Not met: no functional assay exists for p.(Gly2303Arg), and the APC VCEP protein-assay route excludes codon 2303, outside codons 959-2129.
PS4 Not assessed: no proband carrying this variant has documented phenotype points, versus PS4 thresholds of >=16 (very strong) down to 1 (supporting).
PM2 Not met: gnomAD v2.1 non-cancer AF 0.0351% (83/236,496 alleles) exceeds the APC VCEP PM2 threshold of 0.0003% (0.000003) by about 117-fold.
PM5 Not met: no pathogenic or likely pathogenic missense variant exists at residue 2303; the VCEP's only established missense comparators sit at codons 1026 and 1028.
PM6 Not assessed: no assumed-de novo proband observation is recorded, so the minimum de novo score of 0.5 needed for PM6_Supporting cannot be derived.
PP1 Not assessed: no pedigree or meiosis data exists for any family, against the APC PP1_Supporting minimum of 3-4 segregating meioses in one family.
PP3 Not met: the missense-applicable REVEL score 0.611 falls below the 0.644 PP3-supporting threshold, and the VCEP-required SpliceAI splice result was unavailable.
PP5 Not met: the exact-variant ClinVar record has zero expert-panel Pathogenic/Likely pathogenic submissions (all 15 are ordinary single-submitter laboratories).
Benign
BS2 Not met: 1 homozygote in gnomAD v2.1 non-cancer, the VCEP-specified source, versus the >= 2 homozygotes required for BS2 strong.
BS3 Not met: BS3 needs an RNA or beta-catenin protein assay this missense variant at codon 2303 lacks, codons 959-2129 being the framework limit.
BS4 Not assessed: no affected relative tested or reported without the variant, against the BS4 minimum of one affected non-carrier scoring at least 0.5 phenotype points.
BP2 Not met: no in-trans or >=3 unknown-phase co-occurrence with a (likely) pathogenic APC variant is reported for c.6907G>A.
BP5 Not assessed: no alternate-gene (POLD1/POLE/MUTYH/NTHL1/MSH3/MMR) pathogenic finding or colorectal polyposis phenotype is documented to satisfy the categorical BP5 rule.
BP6 Not met: benign/likely benign exact-variant ClinVar assertions come only from ordinary single-submitter laboratories (zero expert-panel submissions), so BP6 is not triggered.
N/A · 8 PM1 · PM3 · PM4 · PP2 · PP4 · BP3 · BP4 · BP7
Research & evidence
Population frequency · supports benign
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 0.000157382; MAF= 0.01574%, 254/1613908 alleles, homozygotes = 3) and has highest observed frequency in the South Asian population (AF= 0.00272306; MAF= 0.27231%, 248/91074 alleles, homozygotes = 3); grpmax FAF= 0.00244403.
v2.1
This variant is present in gnomAD v2.1 (AF= 0.000330661; MAF= 0.03307%, 83/251012 alleles, homozygotes = 1) and has highest observed frequency in the South Asian population (AF= 0.0026137; MAF= 0.26137%, 80/30608 alleles, homozygotes = 1); grpmax FAF= 0.00215168.
🇨🇦 CA
Not available in gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
0.016% · 254 / 1,613,908
3 hom · FAF 0.24%
South Asian
248 / 91,074
0.27%
3 hom
Middle Eastern
1 / 6,062
0.016%
Remaining individuals
4 / 62,498
0.0064%
European (non-Finnish)
1 / 1,179,878
8.5e-05%
+ 6 not observed (Admixed American, European (Finnish), Amish, East Asian, Ashkenazi Jewish, African/African American)
gnomAD v2.1
0.033% · 83 / 251,012
1 hom · FAF 0.22%
South Asian
80 / 30,608
0.26%
1 hom
Remaining individuals
3 / 6,130
0.049%
+ 6 not observed (African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish))
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant has been reported in ClinVar as Likely benign (5 clinical laboratories) and as Uncertain significance (3 clinical laboratories) and as Benign (3 clinical laboratories) and as benign (1 clinical laboratory) and as Likely Benign (1 clinical laboratory). (ClinVarID = 133533)
SpliceAI screenshot
In silico
SpliceAI returned NO scores for this variant, so no SpliceAI-based splice prediction is available. This is missing data, NOT evidence of absent splice impact: it must not be used to support BP4 or to argue against PP3/PVS1. Pangolin scores may be present but are not calibrated for PP3/BP4 here. REVEL score = 0.611. BayesDel score = 0.199863.
Functional / OncoKB screenshot
Functional Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV57373649, n = 4 times).
Hotspots
This variant does not lie in a statistically significant hotspot.
Literature · how each cited paper was used
3papers cited
Each card is an audit: what was searched, what was found, whether it names the variant, which criteria it fed, and why. 5 further PMIDs triaged but not cited — see Sources & references.
Rule & framework references · cited for criterion definitions, not variant evidence
21368914 ↗ Clinical utility gene card for: familial adenomatous polyposis (FAP) and attenuated FAP (AFAP).
25645574 ↗ ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.
25741868 ↗ Standards and guidelines for the interpretation of sequence variants: a joint co
Sources & reference links
9Sources
CSpec VCEP
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC
Cancer hotspots
Triaged references · 5 PMIDs not cited in assessment
20301519 ↗ APC-Associated Polyposis Conditions. CLINVAR
24728327 ↗ Germline variation in cancer-susceptibility genes in a healthy, ancestrally dive CLINVAR
25356965 ↗ ACMG policy statement: updated recommendations regarding analysis and reporting CLINVAR
26389258 ↗ Cancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Versi CLINVAR
26467025 ↗ A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mende CLINVAR